Specific Deuterated Compounds Disclosed in Genus Patents Lack Novelty and Fail the Section 3(d) Therapeutic Efficacy Test Case Summary: 1. Facts: The Appellant challenged the Controller’s rejection of their patent application for deuterated heterocycle-fused gamma-carbolines. The application was refused on grounds of lack of novelty (Section 2(1)(j)), lack of inventive step (Section 2(1)(ja)), and non-patentability (Section 3(d)). The Appellant argued that the compounds were a specific species with improved metabolic stability compared to the known non-deuterated compound "Q". 2. Issue: * Whether specific deuterated compounds are novel if the base formula is covered by prior art Markush/genus disclosures. * Whether improved pharmacokinetic properties (bioavailability/metabolic stability) through deuteration satisfy the "enhanced therapeutic efficacy" requirement under Section 3(d). 3. Ruling: * Novelty: The Court upheld the lack of novelty. Following *AstraZeneca AB* and *Novartis AG*, the Court ruled that if a product is covered in the claims of a prior genus patent (D1 and D7), specific disclosure or "multiple selections" are immaterial. The claimed formulas were inherently disclosed in the prior art. * Section 3(d): The Court held the compounds were "new forms" of a known substance. Relying on *Novartis AG*, it clarified that "efficacy" means therapeutic efficacy, not just physicochemical or pharmacokinetic improvements. * Data Insufficiency: The Appellant's data—showing a 72% increase in parent drug exposure and reduced metabolite formation—demonstrated improved bioavailability/stability but failed to prove a superior therapeutic effect (i.e., treating the disease better). * Conclusion: Increased bioavailability must be specifically linked to enhanced therapeutic efficacy via research data to overcome Section 3(d). The appeal was dismissed.

The Appellant filed Indian Patent Application No. 201817033732 seeking a patent for deuterated heterocycle-fused gamma-carbolines used for treating 5-HT 2A receptor-related disorders

The Appellant claimed that although the base compound (Formula Q) was known, the specific deuterated versions (Formulas I-IV) exhibited unexpectedly improved metabolic stability

The Controller of Patents rejected the application on April 27, 2023, citing lack of novelty under Section 2(1)(j), lack of inventive step under Section 2(1)(ja), and non-patentability under Section 3(d) of the Patents Act, 1970

The Appellant challenged the order, arguing that the Controller conflated distinct legal standards and ignored an expert affidavit regarding therapeutic efficacy

1. Whether the claimed deuterated compounds satisfy the requirement of novelty under Section 2(1)(j) in light of prior art disclosing the genus of the compounds

2. Whether the claimed invention is barred under Section 3(d) as a "new form of a known substance" without a significant enhancement in therapeutic efficacy

The court applied Section 2(1)(j) of the Patents Act regarding novelty and Section 3(d) regarding the non-patentability of derivatives of known substances

specific disclosure is immaterial if a product is "covered" by the claims of a prior genus patent. (AstraZeneca AB v. Intas Pharmaceuticals Ltd. and Boehringer Ingelheim Pharma GMBH & Co. KG v. Vee Excel Drugs)

"efficacy" under Section 3(d) means "therapeutic efficacy" and that increased bioavailability is insufficient unless it translates into enhanced therapeutic benefit proven by research data. (Novartis AG v. Union of India)

Regarding novelty, the court found that Prior Art D1 and D7 already disclosed the chemical formulas resulting in the Appellant's claimed compounds

The court rejected the Appellant’s "multiple selections" argument, holding that if a product is covered by a genus patent, it lacks novelty regardless of whether it was specifically disclosed

Regarding Section 3(d), the court characterized the claimed invention as a derivative of the known "Compound Q"

Reviewing "Example 7" and the co-inventor's affidavit, the court noted that the data showed 72% higher parent drug exposure (bioavailability) and reduced amide formation

However, the court reasoned that under the Novartis standard, improved pharmacokinetic stability or bioavailability does not inherently constitute "therapeutic efficacy"

The Appellant failed to provide clinical data demonstrating that these improved properties resulted in a superior therapeutic outcome on a molecular basis compared to the known substance

It held that the claims lacked novelty under Section 2(1)(j) because they were covered by Prior Art D1 and D7

Furthermore, the claims fell under the Section 3(d) bar because the Appellant failed to prove, via research data, that the improved metabolic stability led to a "significant enhancement of known therapeutic efficacy"

Having upheld the rejection on novelty and Section 3(d) grounds, the court declined to rule on the issue of inventive step